Volume 29, Issue 4 (6-2023)
Intern Med Today 2023, 29(4): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammadzadeh H, Mokhtari-Kheibari A, Mohammadzadeh F, Amani M. Comparison of Salicylic Acid 40% vs. Salicylic Acid 30% with and without Oral Doxycycline in Treating Moderate Acne Vulgaris: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. Intern Med Today 2023; 29 (4)
URL: http://imtj.gmu.ac.ir/article-1-4089-en.html
URL: http://imtj.gmu.ac.ir/article-1-4089-en.html
1- Department of Dermatology, Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Razavi Khorasan, Iran
2- Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Razavi Khorasan, Iran
3- Department of Epidemiology and Biostatistics, School of Health of Health, Gonabad University of Medical Sciences, Gonabad, Razavi Khorasan, Iran
4- Department of Dermatology, Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Razavi Khorasan, Iran ,ml.amani@yahoo.com
2- Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Razavi Khorasan, Iran
3- Department of Epidemiology and Biostatistics, School of Health of Health, Gonabad University of Medical Sciences, Gonabad, Razavi Khorasan, Iran
4- Department of Dermatology, Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Razavi Khorasan, Iran ,
Abstract: (27 Views)
Aims: Acne vulgaris is a cutaneous disorder that affects many individuals. Therapeutic modalities are various, with different outcomes. Chemical peels and antibiotics are effective and safe options for treating acne. This study aimed to compare the salicylic acid (SA) peel 40% vs. the SA peel 30% with and without doxycycline in treating moderate acne vulgaris.
Materials & Methods: In total, 78 subjects with moderate acne vulgaris were enrolled and divided into three groups. Group A received doxycycline plus SA peel 30%, Group B received SA peel 30% plus placebo, and Group C received SA peel 40% plus placebo. Outcomes were evaluated by a blinded dermatologist based on the number of lesions and the Michaelson Acne Score (MAS).
Findings: The MAS, comedones, papules, and pustules decreased by the end of treatment in all groups. There was no difference among the three groups regarding the improvement of comedones, papules, and MAS. However, pustules significantly improved in Group A, compared to the other groups. Evaluation by a blinded dermatologist showed the best improvement in clinical manifestations in Group A.
Conclusion: Doxycycline plus SA peel 30% had superiority to SA monotherapy (even with a higher concentration) in treating inflammatory lesions of acne vulgaris. Combining modalities with different mechanisms achieves better outcomes than monotherapy.
Materials & Methods: In total, 78 subjects with moderate acne vulgaris were enrolled and divided into three groups. Group A received doxycycline plus SA peel 30%, Group B received SA peel 30% plus placebo, and Group C received SA peel 40% plus placebo. Outcomes were evaluated by a blinded dermatologist based on the number of lesions and the Michaelson Acne Score (MAS).
Findings: The MAS, comedones, papules, and pustules decreased by the end of treatment in all groups. There was no difference among the three groups regarding the improvement of comedones, papules, and MAS. However, pustules significantly improved in Group A, compared to the other groups. Evaluation by a blinded dermatologist showed the best improvement in clinical manifestations in Group A.
Conclusion: Doxycycline plus SA peel 30% had superiority to SA monotherapy (even with a higher concentration) in treating inflammatory lesions of acne vulgaris. Combining modalities with different mechanisms achieves better outcomes than monotherapy.
Type of Study: Original |
Subject:
Diseases
Received: 2025/06/18 | Accepted: 2025/09/13 | Published: 2023/06/30
Received: 2025/06/18 | Accepted: 2025/09/13 | Published: 2023/06/30
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |